Wajant H, Pfizenmaier K, Scheurich P
Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany.
Apoptosis. 2002 Oct;7(5):449-59. doi: 10.1023/a:1020039225764.
TNF-related apoptosis-inducing ligand (TRAIL/APO-2L) is a typical member of the TNF ligand family that induces apoptosis by activating the death receptors TRAIL-R1 and TRAIL-R2. TRAIL has attracted great attention in recent years as a promising anti cancer reagent because recombinant soluble TRAIL derivatives induce apoptosis in a broad range of tumor cells but not or only rarely in non-transformed cells. In this review we will address the putative role of TRAIL in cancer treatment in the light of the emerging importance of TRAIL in tumor surveillance and discuss the molecular basis of the cooperation of TRAIL and chemotherapeutic drugs. In particular, we debate controversial data in the literature concerning the cytotoxicity of different TRAIL derivatives on primary human cells.
肿瘤坏死因子相关凋亡诱导配体(TRAIL/APO-2L)是肿瘤坏死因子配体家族的典型成员,它通过激活死亡受体TRAIL-R1和TRAIL-R2来诱导细胞凋亡。近年来,TRAIL作为一种有前景的抗癌试剂备受关注,因为重组可溶性TRAIL衍生物能在多种肿瘤细胞中诱导凋亡,但在未转化细胞中不诱导或很少诱导凋亡。在这篇综述中,鉴于TRAIL在肿瘤监测中日益重要的作用,我们将探讨TRAIL在癌症治疗中的假定作用,并讨论TRAIL与化疗药物协同作用的分子基础。特别是,我们对文献中关于不同TRAIL衍生物对原代人细胞细胞毒性的有争议的数据进行了辩论。